These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28456943)

  • 1. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosfomycin: Resurgence of an old companion.
    Sastry S; Doi Y
    J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of fosfomycin in treating multidrug-resistant infections in children.
    Williams PC
    J Paediatr Child Health; 2020 Jun; 56(6):864-872. PubMed ID: 32294306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
    Darlow CA; Docobo-Perez F; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Gastine S; Kolamunnage-Dona R; de Costa RMA; Ellis S; Franceschi F; Standing JF; Sharland M; Neely M; Piddock L; Das S; Hope W
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0029321. PubMed ID: 33972238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Darlow CA; da Costa RMA; Ellis S; Franceschi F; Sharland M; Piddock L; Das S; Hope W
    Paediatr Drugs; 2021 Sep; 23(5):465-484. PubMed ID: 34435316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
    Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
    Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?
    Dimopoulos G; Koulenti D; Parker SL; Roberts JA; Arvaniti K; Poulakou G
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):201-210. PubMed ID: 30668931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inadequate use of antibiotics and increase in neonatal sepsis caused by resistant bacteria related to health care assistance: a systematic review.
    Silva ACB; Anchieta LM; Lopes MFP; Romanelli RMC
    Braz J Infect Dis; 2018; 22(4):328-337. PubMed ID: 30125532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.
    Parker S; Lipman J; Koulenti D; Dimopoulos G; Roberts JA
    Int J Antimicrob Agents; 2013 Oct; 42(4):289-93. PubMed ID: 23880170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.
    Traunmüller F; Popovic M; Konz KH; Vavken P; Leithner A; Joukhadar C
    Clin Pharmacokinet; 2011 Aug; 50(8):493-503. PubMed ID: 21740073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin in the pediatric setting: Evidence and potential indications.
    Baquero-Artigao F; Del Rosal Rabes T
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):55-61. PubMed ID: 31131593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
    Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
    Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monural--new antibiotic with single intake for treatment of acute cystitis].
    Akush Ginekol (Sofiia); 2008; 47(4):56. PubMed ID: 19227768
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
    Darlow CA; Parrott N; Peck RW; Hope W
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):464-475. PubMed ID: 38108548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.
    Darlow CA; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock LJV; Das S; Hope W
    J Antimicrob Chemother; 2022 Apr; 77(5):1334-1343. PubMed ID: 35170719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.
    Obiero CW; Williams P; Murunga S; Thitiri J; Omollo R; Walker AS; Egondi T; Nyaoke B; Correia E; Kane Z; Gastine S; Kipper K; Standing JF; Ellis S; Sharland M; Berkley JA;
    Arch Dis Child; 2022 Sep; 107(9):802-810. PubMed ID: 35078765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.